Investing.comCodex · 实盘不做把握 5/10不做原因:风险收益比不佳
北京时间·🕒 发布 04:12:31·⟳ 抓取 04:13:34 +1m03s·⚡ 决策 08-29 04:15:00 +1m26s·59.6 天前
Shuttle Pharmaceuticals未按期提交二季度10-Q并收到Nasdaq不合规通知
事件方向偏负面，但不是立即退市或停牌，10-Q无法按期提交的核心事实已在SEC NT 10-Q中提前出现，且无法取得stock_tools正式报价用于ENTER；盘后也不可成交，因此不做新仓。
📄 原文Investing.com↗ 原文
Shuttle Pharmaceuticals fails to meet Nasdaq filing requirements
Wall Street lower as hawkish Warsh at Jackson Hole offsets Mag 7 gains GAITHERSBURG, Md. - Shuttle Pharmaceuticals Hold…
不做 Shuttle Pharmaceuticals Holdings, Inc.（SHPH.US）
不做新仓：事件偏负面但非立即退市或停牌，10-Q迟交事实已在8月17日NT 10-Q提前披露，盘后不可成交且缺少stock_tools正式可执行报价支持ENTER。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
本次消息确认SHPH因迟交二季度10-Q收到Nasdaq 5250(c)(1)不合规通知，属于公司治理和上市合规负面；但正文明确暂无即时上市或交易影响，恢复合规仍有计划提交和最长180天例外期，核心迟交事实在2026年8月17日NT 10-Q已披露，短线做空的新增预期差不足。
消息传播链
- 公司提交NT 10-Q，披露截至2026年6月30日季度的10-Q无法按期提交，这是本次Nasdaq不合规通知的前置事实。
- Investing.com报道公司收到Nasdaq 5250(c)(1)不合规通知，并称通知对上市和交易暂无即时影响。市场反应:美股已收盘，信号时处于盘后不可成交状态。
关键理由
- 迟交10-Q和Nasdaq不合规通知会抬升退市与信息披露风险，但当前只是合规流程起点而非立即退市。
- 量级上，公司市值约200万至230万美元、近年无实质收入且TTM亏损约1082万美元，合规风险对融资与上市资格的边际影响大于经营收入影响。
- 8月17日SEC NT 10-Q已提前披露无法按期提交二季度10-Q，8月28日Nasdaq通知的新增冲击有限。
主要风险
- 若公司未能在10月27日前提交合规计划或Nasdaq不接受计划，退市风险会升级，届时才可能形成更强做空催化。
- SHPH为极小市值低流动性股票，盘后不可成交且短线价格容易受少量成交扭曲。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-28 · 影响 weakens
报道明确称Nasdaq通知对普通股上市或交易暂无即时影响，削弱立即做空强度。
检索:Shuttle Pharmaceuticals Nasdaq non compliance no immediate effect listing trading Form 10-Q 原文 ↗ - 做空前查反向 · 来源 filing · 日期 2026-08-17 · 影响 weakens
SEC已于8月17日披露NT 10-Q，核心迟交事实并非8月28日首次出现，降低新增预期差。
检索:SHPH NT 10-Q June 30 2026 SEC filed August 17 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使本次只保留风控负面，不升级为ENTER SHORT。
方向:未取得可用于event_study的同市场同机制干净先例；规则层面看，该类迟交10-Q通知偏负面但通常弱于立即退市、停牌或正式摘牌决定。
涨幅量级:缺少高相似先例校准，不使用历史幅度设定交易止盈止损。
形态:本轮未形成可交易先例样本，不能据此支持短线做空。
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 1,957 字
Wall Street lower as hawkish Warsh at Jackson Hole offsets Mag 7 gains
GAITHERSBURG, Md. - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced today that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) after failing to file its quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2026, by the required due date.
The company stated it intends to file the Form 10-Q as soon as practicable, according to a press release statement. Shuttle Pharmaceuticals is required to submit a compliance plan to Nasdaq by October 27, 2026, outlining steps to regain compliance.
If Nasdaq accepts the company’s plan, it can grant an exception of up to 180 calendar days from the Form 10-Q due date, or until February 22, 2027, for the company to regain compliance. The company noted there is no assurance that Nasdaq will accept its compliance plan or that it will regain compliance within any extension period granted.
The notice has no immediate effect on the listing or trading of the company’s common stock. Nasdaq maintains a publicly available list of non-compliant companies, which will include Shuttle Pharmaceuticals beginning approximately September 4, 2026. An indicator reflecting the company’s non-compliance will be broadcast over Nasdaq’s market data dissemination network and made available to third-party market data providers.
If the company fails to regain compliance within the required timeframe, its common stock will be subject to delisting from Nasdaq.
Shuttle Pharmaceuticals owns a pharmaceutical software platform for molecular discovery and early-stage drug development. The company’s wholly-owned subsidiary, United Dogecoin, is a digital infrastructure company focused on computing infrastructure supporting blockchain networks, artificial intelligence, and high-performance computing workloads.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
GAITHERSBURG, Md. - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) announced today that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) after failing to file its quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2026, by the required due date.
The company stated it intends to file the Form 10-Q as soon as practicable, according to a press release statement. Shuttle Pharmaceuticals is required to submit a compliance plan to Nasdaq by October 27, 2026, outlining steps to regain compliance.
If Nasdaq accepts the company’s plan, it can grant an exception of up to 180 calendar days from the Form 10-Q due date, or until February 22, 2027, for the company to regain compliance. The company noted there is no assurance that Nasdaq will accept its compliance plan or that it will regain compliance within any extension period granted.
The notice has no immediate effect on the listing or trading of the company’s common stock. Nasdaq maintains a publicly available list of non-compliant companies, which will include Shuttle Pharmaceuticals beginning approximately September 4, 2026. An indicator reflecting the company’s non-compliance will be broadcast over Nasdaq’s market data dissemination network and made available to third-party market data providers.
If the company fails to regain compliance within the required timeframe, its common stock will be subject to delisting from Nasdaq.
Shuttle Pharmaceuticals owns a pharmaceutical software platform for molecular discovery and early-stage drug development. The company’s wholly-owned subsidiary, United Dogecoin, is a digital infrastructure company focused on computing infrastructure supporting blockchain networks, artificial intelligence, and high-performance computing workloads.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。